Stockscreener 앱 받기
6.57
1.20%
-0.08
시간 외 거래:
6.57
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Squarepoint Ops LLC Acquires Significant Stake in Cartesian Ther - GuruFocus
Bear Alert: Why is Cartesian Therapeutics Inc stock going downPrice Action & AI Driven Stock Reports - baoquankhu1.vn
Cartesian Therapeutics (RNAC) director Michael Singer gifts 6,555 shares - Stock Titan
Squarepoint entities disclose multi-affiliate stakes in Cartesian Therapeutics (RNAC) — 8.3% each - Stock Titan
Published on: 2026-03-13 09:11:18 - baoquankhu1.vn
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch - TipRanks
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Growth Recap: Does Cartesian Therapeutics Inc have declining or rising EPS2026 Retail Activity & Stock Portfolio Risk Management - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Myasthenia Gravis Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart.com
Wedbush Reiterates 'Outperform' Rating on RNAC | RNAC Stock News - GuruFocus
Cantor Fitzgerald upgrades Cartesian Therapeutics (RNAC) - MSN
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded to “Overweight” at Cantor Fitzgerald - Defense World
BTIG reiterates Buy on Cartesian Therapeutics stock, $44 target By Investing.com - Investing.com Canada
Cartesian Therapeutics Reports 2025 Financial Results, Advances Descartes-08 Cell Therapy in Autoimmune Diseases and Myasthenia Gravis Phase 3 Trial - Minichart
Mizuho reiterates Cartesian Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Cartesian Therapeutics (RNAC) Upgraded to Overweight by Cantor F - GuruFocus
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics, Inc. 2025 Annual Report – Pipeline, Clinical Trials, Regulatory Approvals, and Competitive Landscape - Minichart
Cantor Fitzgerald Upgrades Cartesian Therapeutics (NASDAQ:RNAC) to Overweight - MarketBeat
Cartesian Therapeutics Inc expected to post a loss of 85 cents a shareEarnings Preview - TradingView
Cartesian Therapeutics posts full year 2025 financial results and issues business update - Traders Union
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics (NASDAQ:RNAC) Issues Earnings Results, Misses Estimates By $0.56 EPS - MarketBeat
Cartesian Therapeutics 2025 10-K: Revenue $2.8M, Net Loss $130.3M - TradingView
[8-K] Cartesian Therapeutics, Inc. Reports Material Event | RNAC SEC FilingForm 8-K - Stock Titan
Cartesian backs MG cell therapy trials with $126.9M cash runway into 2027 - Stock Titan
RNAC SEC FilingsCartesian 10-K, 10-Q, 8-K Forms - Stock Titan
Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation - MSN
Cartesian Therapeutics (RNAC) to Release Earnings on Thursday - MarketBeat
Published on: 2026-03-02 22:13:30 - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cartesian Therapeutics to present at TD Cowen Health Care Conference in Boston - Traders Union
RNAC Should I Buy - Intellectia AI
Cartesian Therapeutics, Inc. (RNAC): Biotechnology Innovator With A 350% Potential Upside - DirectorsTalk Interviews
Cartesian Therapeutics, Inc. (RNAC) upgraded to buy: What does it mean for the stock? - MSN
Published on: 2026-02-25 09:47:28 - baoquankhu1.vn
Aug Sentiment: What is the earnings history of Cartesian Therapeutics IncWeekly Market Outlook & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Cell therapy biotech Cartesian Therapeutics plans 3 investor events - Stock Titan
Cartesian Therapeutics: Clinical Pipeline Progress Under Investor Scrutiny () - aktiencheck.de
What drives Cartesian Therapeutics Inc.’s stock priceQuarterly Trade Review & Real-Time Buy Zone Alerts - mfd.ru
Institution Moves: What’s the MACD signal for Cartesian Therapeutics Inc.2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru
Cartesian Therapeutics, Inc. (RNAC) Investor Outlook: Unpacking a 435.71% Potential Upside in Biotech - DirectorsTalk Interviews
Analyst Upgrade: Is Cartesian Therapeutics Inc attractive for institutional investorsEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Trading Recap: What are Zenas BioPharma Incs growth leversMarket Trend Review & Verified Entry Point Detection - baoquankhu1.vn
Is Cartesian Therapeutics Inc. stock positioned well for digital economyTrade Volume Summary & Community Verified Trade Signals - mfd.ru
Is Cartesian Therapeutics Inc.’s ROE strong enoughWeekly Gains Report & Risk Managed Investment Entry Signals - mfd.ru
FMR LLC Reduces Stake in Cartesian Therapeutics Inc: A Strategic Portfolio Adjustment - GuruFocus
Is Cartesian Therapeutics Inc. a defensive stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Can JCTC stock outperform in a bear market2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 420% Potential Upside in Biotechnology - DirectorsTalk Interviews
Cartesian Therapeutics (RNAC) Issues New Stock Options to Employ - GuruFocus
Cartesian Therapeutics Announces New Employment Inducement Grants - marketscreener.com
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 0.6%Here's What Happened - MarketBeat
Will Cartesian Therapeutics (NASDAQ:RNAC) Spend Its Cash Wisely? - simplywall.st
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Can a 388.62% Upside Fuel Your Investment Strategy? - DirectorsTalk Interviews
Smart Money: Is Cartesian Therapeutics Inc trading at a discountJuly 2025 Trends & Weekly High Return Stock Forecasts - baoquankhu1.vn
Stop Loss: Will Cartesian Therapeutics Inc outperform during market ralliesJuly 2025 Momentum & Real-Time Volume Spike Alerts - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):